CDP 484

Drug Profile

CDP 484

Latest Information Update: 27 Sep 2006

Price : $50

At a glance

  • Originator Celltech Group; UCB
  • Developer Celltech Group
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Immunological disorders; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 26 Sep 2006 Discontinued - Preclinical for Inflammation in United Kingdom (SC)
  • 26 Sep 2006 Discontinued - Phase-I/II for Rheumatoid arthritis in United Kingdom (SC)
  • 26 Sep 2006 Discontinued - Preclinical for Immunological disorders in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top